MVA HAV / University of Oxford, HAV Vaccines - LARVOL DELTA

A phase 1b clinical trial to determine the safety, tolerability and immunogenicity of simian adenovirus and poxvirus vectored vaccines against Mycobacterium avium complex subspecies in patients with active Crohn's disease. (PubMed, EBioMedicine) - "Candidate vaccines ChAdOx2 HAV and MVA HAV were safe, well-tolerated and immunogenic in patients with active CD. A heterologous prime-boost schedule induces a T cell-mediated immune response. Further studies are required to determine the efficacy and optimal regime of the vaccines."

Journal • P1 data • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Respiratory Diseases • Tuberculosis

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=28; Completed; Sponsor: University of Oxford; Recruiting ➔ Completed

Clinical • Trial completion

A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccines ChAdOx2 HAV and MVA in Healthy Adult Volunteers (clinicaltrials.gov) - P1; N=28; Recruiting; Sponsor: University of Oxford; Trial completion date: Sep 2019 ➔ Jan 2020; Trial primary completion date: Sep 2019 ➔ Jan 2020

Clinical • Trial completion date • Trial primary completion date